An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation.

A trial of clomipramine in the treatment of premature ejaculation is described. For the first 4 weeks the drug was administered in a double-blind manner and compared with matching placebo, the two medications being randomly assigned to suitable patients. During the second month patients 'crossed over' to the alternative therapy. Following the completion of the double-blind period all patients received clomipramine for a further 3 months. The drug was administered initially in a dose of 10 mg daily with an option to increase in individual cases to 40 mg. Twenty patients entered the trial, sixteen completed it. During the double-blind study no difference could be shown between clomipramine and placebo in their effect on premature ejaculation. But during the follow-up period nine patients were found to have derived benefit from combined treatment.

RCT Entities:   Population Interventions Outcomes